Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(166 products)
- Bcr-Abl(118 products)
- EGFR(582 products)
- FAK(72 products)
- FLT(86 products)
- Fibroblast Growth Factor Receptor (FGFR)(180 products)
- JAK(243 products)
- PDGFR(129 products)
- RAAS(89 products)
- Src(82 products)
- Syk(37 products)
- Thrombin(57 products)
- VDA(2 products)
- VEGFR(242 products)
Show 6 more subcategories
Found 2382 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
AD57
CAS:AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.
Formula:C22H20F3N7OPurity:99.05%Color and Shape:SoildMolecular weight:455.44PROTAC EGFR degrader 14
PROTACEGFRdegrader 14 is a potent and selective EGFR PROTAC degrader with a DC50 value of approximately 2.9 nM against EGFRL858R/T790M/C797S and a Dmax of 93.1%. It induces the selective degradation of EGFRC797S via a VHL and proteasome-dependent mechanism, downregulating EGFR-related transcriptomes. PROTACEGFRdegrader 14 exhibits high selectivity for EGFRWT, induces cell cycle arrest and apoptosis, and effectively inhibits tumor growth. It is applicable for research on non-small cell lung cancer (NSCLC).Color and Shape:Odour SolidVEGFR/PARP-IN-1
VEGFR/PARP-IN-1 (Compound 14b) is a dual inhibitor of VEGFR and PARP with IC50 values of 191 nM and 60.9 nM, respectively.Formula:C29H27N9OPurity:98%Color and Shape:SolidMolecular weight:517.58SNIPER(ABL)-019
SNIPER(ABL)-019, a compound that links Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting aFormula:C60H77ClN12O9SPurity:98%Color and Shape:SolidMolecular weight:1177.85Osteogenic Growth Peptide (10-14) acetate
Osteogenic Growth Peptide (10-14) acetate (Osteogenic Growth Peptide) is a Src inhibitor and an effective mitogen and stimulator of osteogenesis andFormula:C26H33N5O9Purity:98.69%Color and Shape:SolidMolecular weight:559.57Ref: TM-T37603L
1mg205.00€2mg358.00€5mg515.00€10mg737.00€25mg1,125.00€50mg1,521.00€100mg2,052.00€1mL*10mM (DMSO)695.00€JAK2-IN-10
CAS:JAK2-IN-10 (compound 5) is a potent inhibitor of JAK2v617f, with an IC50 value of ≤10 nM.Formula:C33H33D3FN9O2Color and Shape:SolidMolecular weight:612.71ALK protein ligand-1
CAS:ALK protein ligand-1 (Compound A1) is an ALK protein ligand, acting as a ligand for the target protein in PROTACs, demonstrating inhibitory effects on ALK. It is also useful in the synthesis of AP-1.Formula:C24H29ClN6O3SColor and Shape:SolidMolecular weight:517.043Emodic acid
CAS:Emodic acid is a useful organic compound for research related to life sciences. The catalog number is T124807 and the CAS number is 478-45-5.Formula:C15H8O7Color and Shape:SolidMolecular weight:300.222Si5-N14
CAS:Si5-N14 is a key component of siloxane-linked lipid nanoparticles (SiLNP) with properties that enhance vascular repair and exhibit antitumor activity. In transgenic GFP mouse models, Si5-N14 mediates CRISPR-Cas9 editing. In Lewis lung carcinoma (LLC) tumor mouse models, it leads to the knockdown of vascular endothelial growth factor receptor 2 (VEGFR2), producing antitumor effects. Additionally, in mice with virus-induced lung injury, Si5-N14 facilitates the delivery of fibroblast growth factor-2 (FGF-2) mRNA, promoting vascular repair, oxygenation, and improved lung function. Si5-N14 shows potential for research in tumors, pneumonia, and cardiovascular diseases.Formula:C78H160N6O5Si2Color and Shape:SolidMolecular weight:1318.31SA-PA
SA-PA, a self-assembled intracellular PROTAC leveraging azide-alkyne click chemistry, selectively degrades VEGFR-2, PDGFR-β, and EphB4 proteins within U87 cellsFormula:C40H32ClF3N10O8Purity:98%Color and Shape:SolidMolecular weight:873.19BTK degrader-1
CAS:BTK degrader-1 (compound 1), a bifunctional degrader of Bruton's tyrosine kinase (BTK), demonstrates the capability to be conjugated with CD79b and exhibits anti-tumor effects [1].Formula:C52H54F2N8O6Color and Shape:SolidMolecular weight:925.03BTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Color and Shape:Odour SolidDSPE-PEG2000-GE11
DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.Color and Shape:Odour SolidLewis y tetrasaccharide
CAS:Lewis Y tetrasaccharide, a derivative of Lewis X, is an antigen linked to ovarian cancer metastasis and bad prognosis.Formula:C26H45NO19Color and Shape:SolidMolecular weight:675.63PROTAC EGFR degrader 6
CAS:PROTAC EGFR degrader 6 effectively degrades EGFR Del19 in HCC827 cells (DC50=45.2 nM) and induces apoptosis and G1 arrest.Formula:C49H57FN12O5Color and Shape:SolidMolecular weight:913.05HDS 029
CAS:HDS 029 has a wide range of applications in life science related research.Formula:C17H11ClFN5OColor and Shape:SolidMolecular weight:355.76Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH
CAS:Phosphopeptide ligand for the src SH2 domain (IC50 = 1 μM). Blocks src interactions with EGFR and FAK.Formula:C32H46N5O17PPurity:98%Color and Shape:SolidMolecular weight:803.71PROTAC EGFR degrader 9
CAS:PROTACEGFRdegrader 9 (Compound C6) is an orally active, CRBN-based PROTAC EGFR degrader. It has a DC50 of 10.2 nM and a Kd of 240.2 nM against EGFRL858R/T790M/C797S. PROTACEGFRdegrader 9 demonstrates effective degradation activity against various EGFR mutants while not affecting EGFRWT.
Formula:C45H48F3N9O6SMolecular weight:899.98EGFR-IN-144
EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.Formula:C20H17Cl2N3O3Color and Shape:SolidMolecular weight:418.273SIAIS164018 hydrochloride
SIAIS164018 hydrochloride is a PROTAC-based degrader targeting ALK and EGFR, exhibiting IC50 values of 2.5 nM for ALK and 6.6 nM for ALK G1202R.Formula:C43H49Cl2N10O7PPurity:98%Color and Shape:SolidMolecular weight:919.79EGFR-IN-136
EGFR-IN-136 (compound 21v) is a potent inhibitor of EGFR, demonstrating IC50 values of 20.2 nM, 1.2 nM, 2.3 nM, and 12.5 nM for EGFRWT, EGFRLR/TM, EGFR19D/TM/CS, and EGFRLR/TM/CS, respectively. It exhibits antiproliferative and antitumor activities and holds potential for research in non-small cell lung cancer (NSCLC).Formula:C30H36N7O4PColor and Shape:SolidMolecular weight:589.625EGFR/ACK1-IN-1
EGFRT790M/L858R/ACK1-IN-1 (Compound 21a) is a dual inhibitor targeting EGFRT790M/L858R and ACK1 with IC50 values of 23 nM and 263 nM, respectively. This compound effectively inhibits cell proliferation and exhibits antitumor activity.Formula:C22H20ClN7OMolecular weight:433.14179EGFR-IN-151
EGFR-IN-151 (Compound 10) inhibits EGFR and its downstream signaling pathways ERK/STAT3. It effectively suppresses the proliferation of various lung cancer cells, with IC50 values of 11.7, 5.19, 7.32, and 1.53 μM for NCI-H1781, HCC827, NCI-H3255, and NCI-H1975, respectively. Additionally, EGFR-IN-151 hinders colony formation and cell migration in H1975, induces G1 phase cell cycle arrest, and triggers apoptosis in H1975 cells.Color and Shape:Odour SolidLAE-102
LAE-102 is a monoclonal antibody that acts as an antagonist of activin receptor II-A (ACTRIIA/ACVR2). It shows potential for research in the fields of endocrine and metabolic disorders, oncology, and respiratory diseases.Color and Shape:Odour LiquidALK-IN-13
CAS:ALK-IN-13 is an ALK inhibitor.
Formula:C29H39ClN7O2PColor and Shape:SolidMolecular weight:584.1EGFR-PK/JNK-2-IN-1
EGFR-PK/JNK-2-IN-1 (Compound 6c) is a dual inhibitor of EGFR-PK and JNK-2, with IC50 values of 2.7 and 3.0 μM, respectively. It can induce apoptosis and cause cell cycle arrest at various stages. This compound is applicable in cancer research.Formula:C22H17ClN4O3SMolecular weight:452.07099RR-src
CAS:Tyrosine kinase substrate peptideFormula:C64H106N22O21Purity:98%Color and Shape:Lyophilized PowderMolecular weight:1519.66CPD-1224
CAS:CPD-1224, an oral ALK inhibitor derivative, binds cereblon, targets EML4-ALK fusions, and degrades ALK plus L1196M/G1202R mutants.Formula:C43H47ClN8O7SColor and Shape:SolidMolecular weight:855.4EGFR/DHFR-IN-1
EGFR/DHFR-IN-1 (Compound 10e) is a dual inhibitor of EGFR and DHFR, with IC50 values of 0.151 µM and 0.541 µM, respectively. It induces cell cycle arrest in the G0-G1 and S phases.Formula:C24H26N4O5S2Molecular weight:514.13446Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
CAS:Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from mouse JAK2, specifically composed of amino acids 475 to 491.Formula:C88H138N20O34P2Purity:98%Color and Shape:SolidMolecular weight:2082.1FLT3-IN-23
FLT3-IN-23 (compound 15), a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3), exhibits an IC 50 value of 7.42 nM and demonstrates antiproliferative effectsColor and Shape:Odour SolidDD 03-171
CAS:Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Formula:C55H62N10O8Color and Shape:SolidMolecular weight:991.163EGFR-IN-93
EGFR-IN-93 (compound 18) is an allosteric inhibitor of the T790M/L858R double mutant EGFR. It is applicable for research in non-small cell lung cancer (NSCLC).Formula:C22H18FN3O3Molecular weight:391.13322EGFR WT/T790M/L858R-IN-1
EGFRWT/T790M/L858R-IN-1 (compound 10d) is a potent inhibitor of EGFR, demonstrating IC50 values of 0.097, 0.280, and 0.051 μM for EGFRWT, EGFRT790M, and EGFRL858R, respectively. This compound can be utilized in cancer research.Formula:C26H25Cl3N2O3Molecular weight:518.09308BW710
BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.Formula:C28H29FN6O2SColor and Shape:SolidMolecular weight:532.63EGFR-IN-42
EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.Formula:C49H53ClFN5O5Color and Shape:SolidMolecular weight:846.43EGFR-IN-162
EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.Formula:C27H31N3O2Color and Shape:SolidMolecular weight:429.24163FGFR2 degrader 1
FGFR2 degrader1 (compound 28E) is a selective PROTACS degrader of FGFR2, with a DC50 of 0.645 nM. FGFR2 plays a significant role in cancer research.Formula:C40H39Cl2N9O6Molecular weight:811.24004MRG003
MRG003 is an antibody-drug conjugate (ADC) composed of the humanized anti-EGFR IgG1 monoclonal antibody, Becotatug, coupled with MMAE. These components are linked through a valine-citrulline (valine-citrulline) connector, forming the Drug-Linker conjugate VcMMAE within the ADC.Color and Shape:Odour LiquidMRT-7612
MRT-7612 (Compound 4) is a cereblon-based molecular glue degrader targeting tyrosine kinases. It significantly induces the degradation of HCK and LYN, with a comparatively weaker effect on LCK. MRT-7612 is applicable in research related to cancers such as chronic myeloid leukemia, autoimmune disorders, and chronic inflammatory diseases.Color and Shape:Odour SolidCZY43
CZY43 is an HER3 degrader that effectively induces degradation of HER3 in breast cancer SKBR3 cells in a dose- and time-dependent manner. It efficiently inhibits HER3-dependent signaling and cancer cell growth, outperforming Bosutinib.Formula:C42H53Cl2N5O3Color and Shape:SolidMolecular weight:746.808Ranibizumab
CAS:Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121,Purity:98%Color and Shape:LiquidMolecular weight:149.19KDPertuzumab
CAS:Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2Purity:98.00%Color and Shape:LiquidMolecular weight:145.44 kDadALK-3
dALK-3 is a degrader of anaplastic lymphoma kinase (ALK) that effectively induces the degradation of EML4-ALK with a DC50 of 0.182 μM. It exhibits significant antiproliferative activity against H3122 cells and is applicable for tumor research.Formula:C39H45ClN7O5PColor and Shape:SolidMolecular weight:758.245SNIPER(ABL)-013
SNIPER(ABL)-013, a compound that links GNF5 (ABL inhibitor) with Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 ofFormula:C42H52F3N7O8Purity:98%Color and Shape:SolidMolecular weight:839.9Src Inhibitor 4
Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.Formula:C33H34N4O3Color and Shape:SolidMolecular weight:534.648SNIPER(ABL)-039
CAS:SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 ofFormula:C54H68ClN11O9S2Purity:98%Color and Shape:SolidMolecular weight:1114.77FLT3-IN-21
FLT3-IN-21 (compound LC-3), a potent FLT3 inhibitor with an IC50 value of 8.4 nM, induces apoptosis and arrests the cell cycle in the G1 phase.Formula:C20H22FN5O2Color and Shape:SolidMolecular weight:383.42HAT-SIL-TG-1&AT
HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.Formula:C60H69N17O11SColor and Shape:SolidMolecular weight:1236.36PROTAC EGFR degrader 3
CAS:Potent PROTAC EGFR degrader 3; excellent against H1975/HCC827 cells; lysosome-involved mutant degradation.Formula:C60H77N13O5SColor and Shape:SolidMolecular weight:1092.4FLT3-ITD-IN-2
FLT3-ITD-IN-2 (Compound A1) is an inhibitor of the FLT3-ITD kinase, exhibiting an IC50 of 2.12 nM. It effectively suppresses the proliferation of the FLT3-dependent human AML cell line MOLM-13, with an IC50 of 25.65 nM. FLT3-ITD-IN-2 demonstrates antitumor activity against acute myeloid leukemia.Formula:C39H50N8O6Color and Shape:SolidMolecular weight:726.86EGFR-IN-86
EGFR-IN-86 (compound 4i), an EGFR inhibitor (IC50: 1.5 nM), demonstrates potent activity against glioblastoma by inducing apoptosis and causing G2/M phase cellFormula:C20H21N7O2SPurity:98%Color and Shape:SolidMolecular weight:423.49VEGFR-2-IN-66
VEGFR-2-IN-66 (Compound 6) is an orally active VEGFR-2 inhibitor with an IC50 of 0.509 µM and an IC50 value of 7.48 μM for inhibiting MCF-7 cell proliferation. Its anticancer activity is exerted through cell cycle arrest, induction of apoptosis (Apoptosis), and modulation of gene expression, making it suitable for breast cancer research.Color and Shape:Odour SolidhCA/VEGFR-2-IN-3
hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide with potential as a dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2.Formula:C24H28N6O6SPurity:98%Color and Shape:SolidMolecular weight:528.58SA-VA
SA-VA, an intracellular self-assembled PROTAC featuring azide and alkyne groups, selectively degrades VEGFR-2 and EphB4 proteins within U87 cells.Formula:C50H53ClF3N11O7SPurity:98%Color and Shape:SolidMolecular weight:1044.54FW-1
FW-1 is a type I inhibitor of FLT3, with an IC50 of approximately 1 μM. It exhibits cytotoxic effects in FLT3-mutant AML cells, causes cell cycle arrest at the G0/G1 phase, and induces apoptosis in MV4-11 and MOLM-13 cells.
Formula:C24H27N7OColor and Shape:SolidMolecular weight:429.517SJ1008030
CAS:SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.
Formula:C42H43N13O7SColor and Shape:SolidMolecular weight:873.94FLT3 Ligand-Linker Conjugate 1
CAS:FLT3 Ligand-Linker Conjugate 1 consists of an FLT3 ligand and a PROTAC linker that can recruit E3 ligase VHL. This conjugate is useful for synthesizing PROTAC RSS0680, a bifunctional compound designed for targeted protein degradation of kinases.Formula:C29H34N6O4S2Color and Shape:SolidMolecular weight:594.748EGFR/BRAFV600E-IN-3
EGFR/BRAFV600E-IN-3 is an inhibitor targeting EGFR, BRAFV600E, and EGFRT790M with IC50 values of 57 nM, 68 nM, and 9.70 nM, respectively.Formula:C25H18N4O3Purity:98%Color and Shape:SolidMolecular weight:422.44BRK inhibitor P21d hydrochloride
CAS:BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Formula:C23H23ClFN7O2Color and Shape:SolidMolecular weight:483.93EGFR/VEGFR2-IN-5
EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.Formula:C17H15N7O5SColor and Shape:SolidMolecular weight:429.41FAK-IN-27
FAK-IN-27 (compound 8A) is a potent and selective inhibitor of FAK, with an IC50 of 4.968 nM. It effectively inhibits the proliferation of H1299 cells, with an IC50 of 0.28 μM, and is applicable for research in non-small cell lung cancer (NSCLC).Formula:C32H28ClN5O6Color and Shape:SolidMolecular weight:613.17281EGFR/BRAFV600E-IN-4
EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.Formula:C22H16N4OSColor and Shape:SolidMolecular weight:384.45LH168
LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.Formula:C29H31F3N6O2SColor and Shape:SolidMolecular weight:584.66FGFRs-IN-1
FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.Formula:C28H26Cl2N4O3Color and Shape:SolidMolecular weight:537.44JAK3-IN-14
CAS:JAK3-IN-14 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.Formula:C18H13N3OPurity:98.29%Color and Shape:SoildMolecular weight:287.32Ref: TM-T67754
1mg167.00€5mg409.00€10mg595.00€25mg888.00€50mg1,234.00€100mg1,665.00€1mL*10mM (DMSO)358.00€MY-1576
MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.Formula:C25H29ClN8O2Color and Shape:SolidMolecular weight:509HER2-IN-14
CAS:HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.Formula:C26H23ClF2N8O3Color and Shape:SolidMolecular weight:568.96Multi-kinase-IN-6
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that effectively impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2.Purity:98%Color and Shape:Odour SolidFGFR1/VEGFR2-IN-1
FGFR1/VEGFR2-IN-1 (compound 2b) is an inhibitor of both FGFR1 and VEGFR2, applicable in cancer research [1].Formula:C26H27N4O6PPurity:98%Color and Shape:SolidMolecular weight:522.49EGFR T790M/L858R-IN-9
EGFRT790M/L858R-IN-9 (Compound 8) is an inhibitor targeting the EGFR-L858R/T790M mutations. It effectively inhibits the phosphorylation of the EGFR-L858R/T790M mutant kinase, demonstrating an IC50 value of 0.0064 µM. Additionally, EGFRT790M/L858R-IN-9 can suppress the proliferation of non-small cell lung cancer (NSCLC) cells, making it useful for cancer research.Formula:C26H27N7O3SColor and Shape:SolidMolecular weight:517.603MET/PDGFRA-IN-1
MET/PDGFRA-IN-1 (compound 8c) serves as an inhibitor of MET and PDGFRA proteins, displaying an IC50 of 36 μM against MET.Formula:C26H23N7OPurity:98%Color and Shape:SolidMolecular weight:449.51TYVPANASL TFA
TYVPANASL TFA, a nine-amino-acid MHC I-binding CD8 T-cell epitope derived from HER2/neu, is utilized in the formulation of J-LEAPS vaccines [1].Color and Shape:Odour SolidU3-1784
U3-1784 is a humanized monoclonal antibody targeting CD334, with anti-cancer activity, used in liver cancer research.Color and Shape:LiquidMolecular weight:143.22 kDaAmuvatinib hydrochloride
CAS:Amuvatinib HCl (MP470 HCl) is a multi-targeted oral tyrosine kinase inhibitor and hinders RAD51-mediated DNA repair, exhibiting anticancer properties.Formula:C23H22ClN5O3SPurity:98%Color and Shape:SolidMolecular weight:483.97SIAIS100
SIAIS100, a potent BCR-ABL PROTAC degrader, demonstrates a DC50 value of 2.7 nM, highlighting its efficacy.Formula:C44H50ClF2N9O5SColor and Shape:SolidMolecular weight:890.44ALK-IN-29
ALK-IN-29 (compound 4c) exhibits inhibitory effects on tyrosine protein kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, displaying a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is applicable in cancer research.Formula:C29H32FN3OColor and Shape:SolidMolecular weight:457.58EGFR/VEGFR2-IN-1
EGFR/VEGFR2-IN-1 (Compound 10e) serves as an inhibitor for VEGFR-2 and EGFR, with respective IC50 values of 0.26 and 0.14 μM. It inhibits microtubule protein polymerization with an IC50 of 40.9 μM and induces cell apoptosis (Apoptosis). EGFR/VEGFR2-IN-1 is applicable in research related to anti-leukemia and anti-lymphoma treatments.Color and Shape:Odour SolidDisitamab vedotin
CAS:Disitamab vedotin (RC-48) is a HER2-targeting ADC with MMAE, effective in HER2-expressing gastric cancer.Purity:95.00% - 98%Color and Shape:LiquidMolecular weight:149 kDaSIAIS178
CAS:SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).Formula:C50H62ClN11O6S2Purity:98.07%Color and Shape:SolidMolecular weight:1012.68Ref: TM-T12907
1mg152.00€5mg356.00€10mg485.00€25mg888.00€50mg1,431.00€100mg2,052.00€200mg2,673.00€1mL*10mM (DMSO)393.00€DD0-2363
DD0-2363 (Compound 32d) is a dual-target inhibitor of WDR5-MLL1/HDAC. It can suppress the proliferation of acute myeloid leukemia cells and induce apoptosis. With its antitumor properties, DD0-2363 is applicable for research on acute myeloid leukemia.Formula:C36H36ClFN6O4Color and Shape:SolidMolecular weight:671.16SNIPER(ABL)-024
CAS:SNIPER(ABL)-024, a compound that conjugates GNF5 (ABL inhibitor) to an LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels,Formula:C52H61F3N8O9SPurity:98%Color and Shape:SolidMolecular weight:1031.15MR44397
MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.Formula:C23H26N4O2SColor and Shape:SolidMolecular weight:422.54I-As-1
I-As-1 is a potent inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 of 2.35 nM. It exhibits antiproliferative activity against Ramos cells and OCI-LY10 cells, with IC50 values of 0.52 μM and 0.11 μM, respectively.Formula:C26H27AsN6O2S2Molecular weight:594.08529DBL-6-13
DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.Formula:C25H38N4O3Color and Shape:SolidMolecular weight:442.59VEGFR-2-IN-56
VEGFR-2-IN-56 (compound 12e) exhibits the strongest inhibition activity against VEGFR-2, with an IC50 value of 45.9 nM.Color and Shape:Odour SolidTYD-68
TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.Color and Shape:Odour SolidGlaziovine
CAS:Glaziovine is an agent of anti-ulcerogenic natural alkaloid.Formula:C18H19NO3Purity:98%Color and Shape:SolidMolecular weight:297.35FGFR-IN-19
Arg-IN-1 is a selective covalent inhibitor targeting Arginine (Arg), with IC50 values of 9.7 nM and 30.4 nM for FGFR2 and FGFR3, respectively. This compound is designed to potentially avoid the off-target toxicity of FGFR1/4 and overcome acquired resistance, offering potential in cancer therapies targeting FGFR.Formula:C36H42N12O6Color and Shape:SolidMolecular weight:738.33503Depatuxizumab MMAF
Depatuxizumab-MMAF, an antibody-drug conjugate (ADC), comprises an EGFR-targeted antibody linked to McMMAF and is utilized in glioblastoma research.Color and Shape:LiquidMolecular weight:148.24 kDaAnti-β Klotho Antibody (Fazpilodemab)
CAS:Fazpilodemab (BFKB8488A) is a humanized bispecific antibody that targets and activates the Klotho β and fibroblast growth factor receptor 1c receptor complex.Color and Shape:LiquidMolecular weight:146 kDaZM 449829
CAS:ZM 449829: Selective JAK3 inhibitor, binds to ATP site. pIC50: 6.8 for JAK3, others < 5.0.Formula:C13H10OPurity:98%Color and Shape:SolidMolecular weight:182.222Gefitinib N-oxide hydrochloride
Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.Formula:C22H24ClFN4O41·5HClColor and Shape:SolidMolecular weight:517.59SNIPER(ABL)-049
SNIPER(ABL)-049, a compound that conjugates Imatinib (ABL inhibitor) with Bestatin (IAP ligand) through a linker, effectively reduces BCR-ABL protein levels,Formula:C52H66N10O8Purity:98%Color and Shape:SolidMolecular weight:959.14Itacitinib adipate
CAS:Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.Formula:C32H33F4N9O5Color and Shape:SolidMolecular weight:699.66GW2974
CAS:GW2974, Oral EGFR/ErbB2 dual inhibitor, inhibits glioblastoma multiforme (GBM) cell invasion and tumor growth.Formula:C23H21N7Purity:99.43%Color and Shape:SolidMolecular weight:395.46Lestaurtinib
CAS:Lestaurtinib (CEP 701) is a FLT3 inhibitor that inhibits the phosphorylation of RPTKs and can be used to study leukemia.Formula:C26H21N3O4Purity:99.17%Color and Shape:Off-White SolidMolecular weight:439.46BI-3663
CAS:BI-3663 is a selective PTK2/FAK PROTAC with cereblon ligands, degrading PTK2 (IC50: 18 nM), and shows anti-cancer properties.Formula:C44H42F3N7O12Purity:98%Color and Shape:SolidMolecular weight:917.84DTP3
CAS:DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.Formula:C26H35N7O5Color and Shape:SolidMolecular weight:525.6PND-1186 hydrochloride
CAS:PND-1186 hydrochloride (VS-4718 hydrochloride) is a highly specific, reversible and potent inhibitor of FAK (IC50: 1.5 nM), which can selectively induceFormula:C25H27ClF3N5O3Color and Shape:SolidMolecular weight:537.97
